December 24, 2021 -- It's been a very busy year for scientists and biotech/biomedical professionals. From COVID-19 vaccines to innovations in cell and gene therapies, the field is growing at an unprecedented pace -- with no end in sight. In 2021, ScienceBoard strived to keep our readers updated on the latest news and research in the biopharmaceutical and life sciences fields, along with insights into the people and the innovations behind notable developments.
2020 was a pivotal year for science. The tireless efforts of the scientific community demonstrated the power of science and technology to the greater world. Building on that success and expanding beyond COVID-19, many basic and applied areas of research, including biopharmaceuticals, saw explosive growth. Many of our top stories in 2021 centered around the topics of cell and gene therapy and immunotherapies.
The ScienceBoard team was proud to provide live exclusive coverage of several industry events in 2021, including Meeting on the Mesa and the Society for Immunotherapy of Cancer's annual meeting, where we spoke with key opinion leaders.
Furthermore, based on the results of a member survey, we focused a greater portion of our coverage on the intersection of science and business. We covered Biotech Showcase in January 2021 and will do so again in a few weeks. In addition, we interviewed influential life science investors to explore what types of people and innovations they are seeking. Additionally, our coverage of the BioTools Innovator Accelerator introduced readers to some of the best up-and-coming biotechnology companies.
We anticipate continued growth in all of these areas in 2022, and we look forward to providing our readers with the latest news and insights along the way.
Below is a list of the 10 most-read stories on ScienceBoard in 2021. We hope you enjoyed reading these articles and learned something from us:
- Nobel Prize winner Doudna shares perspectives on future of CRISPR gene editing
- Nanoparticles may offer new way to tackle antibiotic-resistant bacteria
- How one mammalian DNA polymerase challenges the central dogma of biology
- Where is the immunotherapy field headed after COVID-19?
- Variant-resistant COVID-19 vaccines could be effective, cheap to make
- Cardiovascular cell, gene therapy leaders discuss nascent field
- CGTBO editor comments on trends from Cell & Gene Meeting on the Mesa
- Online portal helps screen COVID-19 drug candidates
- Filling a gap so biotech startups can advance to the next level
- Experimental drug enhances immunotherapy against pancreatic cancer in mice
Copyright © 2021 scienceboard.net